Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adenocarcinoma, Allergy, angioedema, antitumor, ascending, billion, bispecific, cavitation, cavity, CINDU, CIU, College, costimulation, couple, CSU, deficiency, degranulation, Delinquent, differentiation, disagreement, disaster, dramatic, Duke, exam, explanatory, gastroesophageal, gene, halt, Hampton, idiopathic, IgE, implicit, inactivating, induction, inhibitory, iniate, itchy, lab, leukotriene, markedly, merit, MSD, node, NOTCH, Omalizumab, onset, outage, outbreak, pain, pandemic, parental, PCT, play, power, protruding, purpose, role, roughly, SCF, scratching, sizeable, somatic, spread, strain, subvert, suppression, surfaced, symptomatic, transient, uPR, urticaria, Wuhan
Removed:
administered, adult, AEs, agonistic, andin, anniversary, assessing, assigned, attack, attributed, BRAF, broadly, calculated, called, CAM, captured, cascade, colorectal, complexity, composition, consummated, correlation, COSO, counterpart, diagnosed, discontinued, EGFR, encountered, enhanced, escalate, explore, fatigue, finalized, forma, gastrointestinal, GIST, glembatumumab, glioblastoma, gpNMB, greatest, growing, Haven, hematologic, Herceptin, highest, horizon, immunologic, impacting, improved, induced, intent, July, knowledge, leverage, LLP, malignant, Medarex, mediated, METRIC, mild, mobilize, moderate, nausea, nivolumab, novelty, ovarian, permissive, pointing, pro, promptly, published, randomized, RCC, recognizing, representing, Rintega, sample, select, sequence, Squibb, stromal, Tafinlar, tangible, Tarceva, theJournal, treating, UltiMab, unaudited, untapped, unusual, vedotin, vigorously, vivo, Zelboraf
Filing tables
Filing exhibits
Related press release
CLDX similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-232253, 333-232255, 333-219867, 333-219869, 333-205694, 333-189336, 333-151728 and 333-117602) and on Form S-3 (Nos. 333-214882 and 333-215747) of Celldex Therapeutics, Inc. of our report dated March 26, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 26, 2020
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM